-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, EA4ngfmcvU7mPEUuTbx79nwr1kCml/CZqrAdaZNQWciE5FELrEaP7cnBX/QtXWPM HwgHANuEqQHMHxzP5RIYOw== 0001193125-10-005621.txt : 20100301 0001193125-10-005621.hdr.sgml : 20100301 20100113122106 ACCESSION NUMBER: 0001193125-10-005621 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20100113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HOLLIS EDEN PHARMACEUTICALS INC /DE/ CENTRAL INDEX KEY: 0000899394 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133697002 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 4435 EASTGATE MALL STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-587-9333 MAIL ADDRESS: STREET 1: 4435 EASTGATE MALL STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: HOLLIS EDEN PHARMACEUTICALS INC /DE/ DATE OF NAME CHANGE: 19970410 FORMER COMPANY: FORMER CONFORMED NAME: INITIAL ACQUISITION CORP DATE OF NAME CHANGE: 19930329 CORRESP 1 filename1.htm Acceleration Request

Hollis-Eden Pharmaceuticals, Inc.

4435 Eastgate Mall, Suite 400

San Diego, California 92121

January 13, 2010

VIA EDGAR

Securities and Exchange Commission

100 F Street, NE

Washington, D.C. 20549

 

Attention: Jeffrey Riedler and Laura Crotty
   Mail Stop 4720

 

  Re: Hollis-Eden Pharmaceuticals, Inc. (the “Company”)
     Registration Statement on Form S-3 (File No. 333-163936)

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the Commission take the appropriate action to cause the above-referenced Registration Statement to become effective at 9:30 a.m. Pacific Daylight Time on Friday, January 15, 2010, or as soon thereafter as possible.

The Company acknowledges that:

 

•  

should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

 

•  

the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

 

•  

the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Sincerely,

 

Hollis-Eden Pharmaceuticals, Inc.

/s/    Robert Weber

Robert Weber
Chief Financial Officer
 -----END PRIVACY-ENHANCED MESSAGE-----